The civic record
Read. Follow. Verify.Congressional Hearing on Prescription Drug Supply Chain and Pricing
Record date · January 1, 2022
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This document is a transcript of a May 9, 2019, House Subcommittee on Health hearing. Lawmakers and industry representatives discussed the complexities of the prescription drug and factors influencing drug prices.
The hearing provides a public record of testimony from pharmaceutical manufacturers and pharmacy benefit managers regarding the mechanisms that determine the final cost of medications for patients.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Pharmaceutical Manufacturers
These companies are subject to legislative scrutiny regarding their pricing models and supply chain practices.
Pharmacy Benefit Managers (PBMs)
PBMs are involved in the supply chain and are subject to oversight regarding their role in drug cost negotiations.
Patients
Patients are the end-users of prescription drugs and are affected by the pricing outcomes resulting from supply chain dynamics.
Key Facts
- The hearing took place on May 9, 2019, before the House Subcommittee on Health.
- The session focused on deconstructing the drug supply chain to understand factors affecting prescription drug prices.
- Testimony was provided by representatives from pharmaceutical manufacturers (Pfizer, Amgen, Exelixis).
- Testimony was provided by representatives from pharmacy benefit managers and pharmacy services (Express Scripts, Navitus Health Solutions, Blue Cross Blue Shield, Ascension).
Show all 5 facts
- The document includes prepared statements and answers to follow-up questions from the witnesses.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at this hearing?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Multi-stakeholder approach to drug pricing
The hearing demonstrates a legislative effort to examine the entire supply chain, including both manufacturers and intermediaries, rather than focusing solely on drug manufacturers.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance60How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools